Dr. Birgitte Volck, M.D. Ph.D., serves as President - Research & Development of the Company. From June 2016 to August 2018, she served as senior vice president and head of research and development, Rare Disease at GlaxoSmithKline plc. Prior to joining GlaxoSmithKline plc, she served as chief medical officer and senior vice president, development at Swedish Orphan Biovitrum (SOBI), a biopharmaceutical company, from 2012 to 2016. Dr. Volck received her M.D. and Ph.D. degrees from Copenhagen University, Denmark.
As the President - Research & Development of AvroBio Inc, the total compensation of Birgitte Volck at AvroBio Inc is $4,384,270. There are no executives at AvroBio Inc getting paid more.
Birgitte Volck is 57, he's been the President - Research & Development of AvroBio Inc since 2018. There are 12 older and 8 younger executives at AvroBio Inc. The oldest executive at AvroBio Inc is Christopher Paige, 67, who is the Independent Director.
Birgitte's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.
Over the last 6 years, insiders at AvroBio Inc have traded over $3,066,308 worth of AvroBio Inc stock and bought 2,395,057 units worth $31,037,133 . The most active insiders traders include Braden Michael Leonard, Bruce Booth y Venture Fund X, L.P.Atlas V.... On average, AvroBio Inc executives and independent directors trade stock every 102 days with the average trade being worth of $206,675. The most recent stock trade was executed by Braden Michael Leonard on 13 May 2024, trading 766,635 units of AVRO stock currently worth $973,626.
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
AvroBio Inc executives and other stock owners filed with the SEC include: